Completed PHASE2 INTERVENTIONAL 1-arm NCT00738582

An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma (Amatuximab)

An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

Sponsor: Morphotek

Conditions Malignant Pleural Mesothelioma

Interventions Cisplatin MORAb-009 (Amatuximab) Pemetrexed

Updated 9 times since 2017 Last updated: Aug 24, 2022 Started: Dec 31, 2008 Primary completion: Jun 30, 2011 Completion: Jan 10, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Malignant Pleural Mesothelioma and is currently completed. Morphotek leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2022 — Jul 2024 [monthly]

Completed PHASE2
Apr 2022 — Sep 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Morphotek

Data source: Morphotek

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Baltimore, United States , Barcelona, Spain , Berlin, Germany , Bethesda, United States , Birmingham, United States , Chicago, United States , Enschede, Netherlands , Gauting, Germany and 17 more locations